Infections are the most commonly reported AEs in patients with RA treated with immunosuppressive therapies, and they can be clinically significant
• A recent review reported differences in the risk of infection for some biologics such as tocilizumab and TNF inhibitors1
• Abatacept selectively modulates T-cell co-stimulation and is approved for the treatment of RA
• In patients with polyarticular-course juvenile idiopathic arthritis, no association was found between higher serum abatacept exposure and the incidence of infection2
— This has not been evaluated for adult patients with RA
By: Paul Emery, Roy Fleischmann, Robert Wong, Karissa Lozenski, Yoshiya Tanaka, Vivian Bykerk, Clifton O Bingham, Thomas WJ Huizinga, Gustavo Citera, Yedid Elbez, Vidya Perera, Bindu Murthy, Kelly Maxwell, Julie Passarell, William Hedrich, and Daphne Williams.
Poster presented at the Annual European Congress of Rheumatology (EULAR); June 1 – 4, 2022; Copenhagen, Denmark.